Autopsy report · NCT05044936
Topical Cannabidiol Cream and Post-exercise Recovery
Cause of deathFunding or business, also regulatory or ethics
“The researchers were not able to acquire funding to initiate the study. Also, the study was not approved by the local IRB which requested a FDA new drug application.”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Early Phase 1
- Sponsor
- University of New Mexico
- Sponsor type
- University, hospital or other
- Conditions
- Muscle Damage
- Interventions
- Cannabidiol Oil; Resistance Exercise
- Participants
- 0
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Iontophoresis in Psoriasis
“FDA did not provide approval of the use of the drug for the study” - Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease
“Study did not receive IRB approval.” - DWIBS-MRI: An Adjunct to the Traditional Diagnostic Breast Imaging Evaluation
“Further funding was not approved for this study” - Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group
“FDA request as study could not serve as the confirmatory trial.” - Open-label, Single-arm, Proof of Concept Study in Subjects with Mild-to-moderate Facial Hyperpigmentation
“This study had been withdrawn by the sponsor as they are in process to approach FDA with rationale to get agency feedback and share written response on IRB query. Thereafter, they may again approach with new application and FDA written response.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.